Last reviewed · How we verify
Subcutaneous injection of TAK-850 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Subcutaneous injection of TAK-850 (Subcutaneous injection of TAK-850) — Takeda.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Subcutaneous injection of TAK-850 TARGET | Subcutaneous injection of TAK-850 | Takeda | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Subcutaneous injection of TAK-850 CI watch — RSS
- Subcutaneous injection of TAK-850 CI watch — Atom
- Subcutaneous injection of TAK-850 CI watch — JSON
- Subcutaneous injection of TAK-850 alone — RSS
Cite this brief
Drug Landscape (2026). Subcutaneous injection of TAK-850 — Competitive Intelligence Brief. https://druglandscape.com/ci/subcutaneous-injection-of-tak-850. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab